REGENXBIO (NASDAQ: RGNX) director granted 9,807 RSUs and 46,600 stock options

Rhea-AI Filing Summary

REGENXBIO Inc. director George V. Migausky reported equity awards that increase his stake in the company. He received 9,807 shares of common stock as a time-based restricted stock unit award that will fully vest on May 29, 2027, contingent on continued service. Following this award, he directly holds 28,861 common shares. He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. These are compensation-related grants rather than open-market purchases or sales.

Insights

Corporate governance analyst

Director received routine stock and option awards tied to continued service.

Director George V. Migausky received 9,807 time-based RSUs and options for 46,600 shares with a $7.01 exercise price, all vesting on May 29, 2027. These grants appear to be standard equity compensation for board service.

The RSUs and options vest only if service continues through May 29, 2027, aligning part of the director’s pay with company performance and tenure. Because there are no open-market buys or sells, the filing mainly updates investors on compensation and ownership levels, without signaling a change in sentiment.

Insider Trade Summary

Net Buyer: 9,807 shares

Net Buy 2 txns

Insider MIGAUSKY GEORGE V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	46,600	$0.00	$0.00
Grant/Award	Common Stock	9,807	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 46,600 shares (Direct); Common Stock — 28,861 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
2. F2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Key Figures

RSU grant: 9,807 shares Options granted: 46,600 options Option exercise price: $7.01 per share +3 more

6 metrics

RSU grant 9,807 shares Time-based RSU award vesting May 29, 2027

Options granted 46,600 options Stock options on common stock granted to director

Option exercise price $7.01 per share Strike price for 46,600 stock options

Common shares held 28,861 shares Director’s direct common stock ownership after RSU grant

Vesting date May 29, 2027 Vesting for RSUs and stock options

Option expiration May 29, 2036 Expiration date for stock options

Key Terms

restricted stock unit award (RSU), Stock Options (Right to Buy), continuous service, vesting

4 terms

restricted stock unit award (RSU) financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) granted with an exercise price of 7.0100."

continuous service financial

"will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer."

vesting financial

"100% of the shares subject to this RSU will vest on May 29, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/02/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGAUSKY GEORGE V

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		9,807(1)	A	$0.00	28,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$7.01	05/29/2026		A		46,600		05/29/2027(2)	05/29/2036	Common Stock	46,600	$0.00	46,600	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)